CrushSCI.com
97.3Average days
83Median days
30Fastest days
201Longest days
1342025 publications

Paper Review Records

All Paper Review Records

15 valid samples · Newest publication first
Review days = acceptance date − received date. PDF, DOI, and publisher-page sources are retained.

186 days

Construction of a lung adenocarcinoma overall survival prognostic model based on monocyte-derived macrophage signature genes and exploration of immune crosstalk plus Pan-Cancer prognostic disparities

Authors
Yong Zhang; Lanbo Liu; Jie Ma; Shihui XiaShow moreShow less
Affiliations
Department of Cardiothoracic Surgery, Xiangyang Central Hospital, Affiliated Hospital of Hubei University of Arts and Science, No. 136, Jingzhou Street, Xiangcheng District, 441106 Xiangyang, Hubei, ChinaShow moreShow less
Source PDF DOI Publisher page
30 days

A novel CD123xVδ2 bispecific T cell engager induces potent and tumor selective Vγ9Vδ2-T cell activity against CD123 expressing acute myeloid leukemia and myelodysplastic syndrome

Authors
Jurjen M. Ruben; Charlotte M. Mousset; Dorien van de Berg; Kim Hofman; Milon de Jong; Patricia Brouwer; Sanne Graeve; Victoria Iglesias-Guimarais; Pauline M. van Helden; Anton E.P. Adang; Rob C. Roovers; Hans J. van der VlietShow moreShow less
Affiliations
Department of Medical Oncology, Amsterdam UMC, location VUmc, Vrije Universiteit Amsterdam, Amsterdam, 1081 HV, the Netherlands; LAVA Therapeutics N.V, Utrecht, the Netherlands; Engager BIO B.V, Amstelveen, the NetherlandsShow moreShow less
Source PDF DOI Publisher page
54 days

Genetic and clinical evidence supports HLA-DR+ CD8+ T cells as a favorable immune biomarker in acute myeloid leukemia

Authors
Gang Chen; Jing Xu; Xiaoyu He; Yixin Yan; Linhui Hu; Zhenjiang LiShow moreShow less
Affiliations
Department of Hematology, The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, ChinaShow moreShow less
Source PDF DOI Publisher page
84 days

Development of bi-functional hybrid IgGA antibodies for enhancing cancer immunotherapy

Authors
Xiuyun Li; Vladislav Rybchenko; Naida Mamaeva; Jingyan Wang; Dmitry Dolgikh; Baohang Lin; Victoria ArgentovaShow moreShow less
Affiliations
Faculty of Biology, Shenzhen MSU-BIT University, Shenzhen 518172, China; Department of Thyroid, Breast and Vascular Surgery, Longgang Central Hospital of Shenzhen, Shenzhen 518000, China; Faculty of Biology, Lomonosov Moscow State University, Moscow 119991, Russia; Shemyakin and Ovchinnikov Institute of Bioorganic Chemistry (IBKh), Russian Academy of Sciences, Moscow 117997, RussiaShow moreShow less
Source PDF DOI Publisher page
90 days

The relationship between autoantibody and complement levels in the sera of patients with systemic lupus erythematosus

Authors
David S. Pisetsky; Yuankang Zhao; Matthew Engelhard; Amanda Eudy; Philip Tedeschi; Tyler O'Malley; Roberta Vezza Alexander; Megan Clowse; Lisa Criscione-Schreiber; Jayanth Doss; Mithu Maheswaranathan; Rebecca Sadun; Kai Sun; Nathaniel Harris; Jennifer RogersShow moreShow less
Affiliations
Duke University School of Medicine, Department of Medicine, Durham, NC, USA; Durham VA Medical Center, Durham, NC, USA; Duke University School of Medicine, Department of Biostatistics & Bioinformatics, Durham, NC, USA; Immunovant, Inc., New York, NY, USA; Exagen, Inc., Vista, CA, USAShow moreShow less
Source PDF DOI Publisher page
127 days

TIM-3 as a therapeutic target in anaplastic thyroid carcinoma: Preclinical and transcriptomic evidence supporting a new immunotherapy avenue

Authors
Monikongkona Boruah; Riyaz Ahmad Mir; Sameer Rastogi; Kapil Sikka; Shipra AgarwalShow moreShow less
Affiliations
Department of Pathology, All India Institute of Medical Sciences (AIIMS), New Delhi, India; Department of Biochemistry, All India Institute of Medical Sciences (AIIMS), New Delhi, India; Department of Medical Oncology, All India Institute of Medical Sciences (AIIMS), New Delhi, India; Department of Otorhinolaryngology and Head and Neck Surgery, All India Institute of Medical Sciences (AIIMS), New Delhi, IndiaShow moreShow less
Source PDF DOI Publisher page

FAQ

How long does CLINICAL IMMUNOLOGY take to review a manuscript?

As of 2026-11-14, CrushSCI has 15 complete review records for CLINICAL IMMUNOLOGY. The fastest paper went from submission to acceptance in 30 days (A novel CD123xVδ2 bispecific T cell engager induces potent and tumor selective Vγ9Vδ2-T cell activity against CD123 expressing acute myeloid leukemia and myelodysplastic syndrome, received 2026-09-22, accepted 2026-10-22); the slowest took 201 days. The average is 97.3 days and the median is 83 days.

Expert Matching · Case Demo

Turn Your Submission Goalsinto a Verifiable Journal Plan

Share your field, deadline, and author profile. CrushSCI uses real review records to suggest a title direction, shortlist journals, and estimate timelines.

We will reply within 30 minutes.

CrushSCI online

Client

I work in environmental engineering and need an SCI paper published within three months. I have no grant funding or prominent co-author. Which journals could I target?

CrushSCI

Yes. We will first screen for feasibility against the 90-day deadline, then identify comparable papers without grant support or prominent co-authors. The final shortlist will prioritize research quality and journal scope.

Suggested title
Machine Learning and Life-Cycle Assessment for Predicting and Optimizing Carbon Emissions in Urban Wastewater Treatment

SampleLatest 5 valid paper samples from 2026

Average review59.6 days

Median65 days

Contact CrushSCI

Contact CrushSCI

Leave your email address to discuss academic polishing, structural refinement, or one-to-one guidance.

We will reply within 30 minutes.

Selected service: Academic Consulting Service

Leave your email address

Or email us directly at leader@crushsci.com

Enter your email address so we can reply. Your details will remain private.